Vaxess Technologies

OverviewSuggest Edit

Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution but also increase access to life-saving products for people around the world. 

TypePrivate
Founded2012
HQCambridge, MA, US
Websitevaxess.com

Latest Updates

Employees (est.) (Jan 2021)20
Cybersecurity ratingBMore

Key People/Management at Vaxess Technologies

Michael Schrader

Michael Schrader

Co-founder, CEO and Director
Kathryn Kosuda

Kathryn Kosuda

Co-Founder, Chief Scientific Officer and Director
Livio Valenti

Livio Valenti

Co-Founder, Senior VP of Strategy, Operations and Business Development.
Jonathan Kluge

Jonathan Kluge

VP of Research and Development
Lynda Tussey

Lynda Tussey

Chief Development Officer
Elizabeth Johansen

Elizabeth Johansen

Director of Product Design
Show more

Vaxess Technologies Office Locations

Vaxess Technologies has an office in Cambridge
Cambridge, MA, US (HQ)
790 Memorial Dr
Show all (1)

Vaxess Technologies Financials and Metrics

Summary Metrics

Founding Date

2012

Vaxess Technologies total Funding

$24.4 m

Vaxess Technologies latest funding size

$8.20 m

Time since last funding

2 years ago

Vaxess Technologies investors

Vaxess Technologies's latest funding round in June 2019 was reported to be $8.2 m. In total, Vaxess Technologies has raised $24.4 m
Show all financial metrics

Vaxess Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Vaxess Technologies Online and Social Media Presence

Embed Graph

Vaxess Technologies Blogs

Solving the challenges of infrastructure, logistics, and manufacturing for COVID-19 Vaccines

The Only Single-Dose, Shelf-Stable, Self-Applied SARS-CoV-2 Vaccine Vaxess continues to advance its single-dose, shelf stable COVID vaccine with support from BARDA. In recent studies, Vaxess has shown that the MIMIX patch leads to a 50x enhancement in immune responses over a traditional IM injection…

Vaxess Technologies Frequently Asked Questions

  • When was Vaxess Technologies founded?

    Vaxess Technologies was founded in 2012.

  • Who are Vaxess Technologies key executives?

    Vaxess Technologies's key executives are Michael Schrader, Kathryn Kosuda and Livio Valenti.

  • How many employees does Vaxess Technologies have?

    Vaxess Technologies has 20 employees.

  • Who are Vaxess Technologies competitors?

    Competitors of Vaxess Technologies include LGC, Fate Therapeutics and Nabriva Therapeutics.

  • Where is Vaxess Technologies headquarters?

    Vaxess Technologies headquarters is located at 790 Memorial Dr, Cambridge.

  • Where are Vaxess Technologies offices?

    Vaxess Technologies has an office in Cambridge.

  • How many offices does Vaxess Technologies have?

    Vaxess Technologies has 1 office.